Stock CRON CRONOS GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Cronos Group Inc.

Cronos Group Inc. Stock price

Equities

CRON

CA22717L1013

Pharmaceuticals

Market Closed - Toronto Stock Exchange
Other stock markets
 04:00:00 2023-12-01 pm EST 		Intraday chart for Cronos Group Inc. 5-day change 1st Jan Change
2.830 CAD +2.54% +2.17% -17.73%
Nov. 27 Cronos Group Edges Down Premarket as it Raises C$23 Million in a Sale and Leaseback of an Ontario Property MT
Nov. 27 Cronos Group Brief: Entering into agreement for the sale-leaseback of its Stayner, Ontario facility MT

Financials

Sales 2023 * 120 M 89.14 M Sales 2024 * 147 M 109 M Capitalization 1,079 M 798 M
Net income 2023 * -49.00 M -36.27 M Net income 2024 * -13.00 M -9.62 M EV / Sales 2023 *
-0,64x
Net cash position 2023 * 1,156 M 856 M Net cash position 2024 * 1,174 M 869 M EV / Sales 2024 *
-0,65x
P/E ratio 2023 *
-21,5x
P/E ratio 2024 *
-61,7x
Employees 447
Yield 2023 *
-
Yield 2024 *
-
Free-Float 52.47%
More Fundamentals * Assessed data

Chart Cronos Group Inc.

Dynamic Chart

Latest news about Cronos Group Inc.

Cronos Group Edges Down Premarket as it Raises C$23 Million in a Sale and Leaseback of an Ontario Property MT
Cronos Group Brief: Entering into agreement for the sale-leaseback of its Stayner, Ontario facility MT
Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. for CAD 23 million. CI
Transcript : Cronos Group Inc., Q3 2023 Earnings Call, Nov 08, 2023 CI
Cronos Group Up 3.7% Premarket as its Q3 Loss Narrows on Sales Gain MT
Cronos Group Brief: Company maintains its expectation that the net change in cash will be positive in 2024 MT
Cronos Group Brief: Anticipates that net change in cash, defined as sum of cash and cash equivalents and short-term investments, will decline by less than US$5-$10 million in the last three months of fiscal year 2023 MT
Cronos Group Brief: Reiterates its previously announced operating expense savings target of US$20-$25 million in 2023, and planned incremental operating expense savings of $10-$15 million in 2024 MT
Cronos Group Brief: Citing "Industry-leading" balance sheet with US$840 million in cash and short-term investment MT
Cronos Group Brief: On a constant currency basis, net revenue in Q3 2023 increased by 27% year-over-year to US$26.0 million MT
Cronos Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cronos Group Brief: Net revenue in Q3 2023 increased by 22% year-over-year to US$24.8 million MT
North American Morning Briefing : Stock Futures -2- DJ
Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis Market CI
Cronos Group Brief: Unveiling its New THCV Products MT
More news

Analyst Recommendations on Cronos Group Inc.

Bernstein Starts Cronos Group at Market Perform with CA$4.10 Price Target MT
Barclays Adjusts Cronos Group's Price Target to $3.50 from $5, Maintains Equalweight Rating MT
Cronos Group Price Target Raised to $7 at Raymond James MT
CIBC Upgrades Cronos Group to Outperform From Neutral MT
Raymond James Adjusts Cronos Group Price Target to $6 From $5, Maintains Outperform Rating MT
More recommendations

Press releases Cronos Group Inc.

Cronos Group Inc. enters into agreement for the sale-leaseback of its Stayner, Ontario facility GL
Cronos Group Inc. enters into agreement for the sale-leaseback of its Stayner, Ontario facility AQ
Ontario Court Refuses To Exclude U.S. Shareholders From Class: The 'Day Of Reckoning' Had Not Yet Dawned AQ
Cronos: Q3 Earnings Snapshot AQ
Cronos Group Reports 2023 Third Quarter Results GL
More press releases

News in other languages on Cronos Group Inc.

Cannabis: Die Branche schwebt wieder auf Wolke sieben
Cannabis: El sector vuelve a dispararse
Cannabis : le secteur plane à nouveau
Bolsa de Madrid: Los osos son liberados
Les ours sont lâchés
More news

Quotes and Performance

1 day+2.54%
1 week+2.17%
Current month+2.54%
1 month+11.86%
3 months+5.99%
6 months+19.41%
Current year-17.73%
More quotes

Highs and lows

1 week
2.58
Extreme 2.58
2.83
1 month
2.51
Extreme 2.51
2.90
Current year
2.15
Extreme 2.145
3.57
1 year
2.15
Extreme 2.145
4.88
3 years
2.15
Extreme 2.145
20.08
5 years
2.15
Extreme 2.145
32.95
10 years
0.14
Extreme 0.14
32.95
More quotes

Managers and Directors - Cronos Group Inc.

Managers TitleAgeSince
Michael Ryan Gorenstein CEO
 Chief Executive Officer 36 2015
James Holm DFI
 Director of Finance/CFO 40 Nov. 13
Arye Weigensberg CTO
 Chief Tech/Sci/R&D Officer 40 -
Members of the board TitleAgeSince
Kendrick F. Ashton BRD
 Director/Board Member 47 2021
James D. Rudyk BRD
 Director/Board Member 56 2018
Jason Adler BRD
 Director/Board Member 51 2016
More insiders

ETFs positioned on Cronos Group Inc.

Name Weight AuM 1st Jan change Investor Rating
HORIZONS MARIJUANA LIFE SCIENCES INDEX ETF - CAD ETF Horizons Marijuana Life Sciences Index ETF - CAD
12.68% 52 M€ -.--% -
More ETFs positioned on Cronos Group Inc.

Quotes

Date Price Change Volume
23-12-01 2.830 +2.54% 149,893
23-11-30 2.760 +3.37% 277,382
23-11-29 2.670 +1.14% 65,055
23-11-28 2.640 -0.75% 107,709
23-11-27 2.660 -3.97% 60,081

Delayed Quote Toronto Stock Exchange, December 01, 2023 at 04:00 pm EST

More quotes

Company Profile

Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company’s segments include United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s international brand portfolio includes Spinach, PEACE NATURALS, Lord Jones, Happy Dance and PEACE+. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s subsidiaries include Cronos Israel G.S. Cultivation Ltd., Cronos Israel G.S. Manufacturing Ltd., Cronos Israel G.S. Store Ltd., and Cronos Israel G.S. Pharmacy Ltd.
Sector
Pharmaceuticals
Calendar
2024-02-26 - Q4 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Cronos Group Inc.

Trading Rating :
Investor Rating :
ESG Refinitiv :
D-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
2.830CAD
Average target price
3.378CAD
Spread / Average Target
+19.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
CRONOS GROUP INC. Stock Cronos Group Inc.
-17.73% 799 M $
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-16.96% 5 823 M $
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+25.11% 4 594 M $
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+82.30% 3 269 M $
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
+42.10% 3 200 M $
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-15.14% 2 763 M $
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
+13.01% 2 156 M $
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-20.42% 1 902 M $
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
+4.60% 1 767 M $
GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. Stock Guizhou Bailing Group Pharmaceutical Co., Ltd.
+1.23% 1 603 M $
Alternative Medicine
  1. Stock
  2. Equities
  3. Stock Cronos Group Inc. - Toronto Stock Exchange
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer